Today, Eli Lilly and Co. (LLY) Earns Outperform Rating from Leerink Swann

Today, Eli Lilly and Co. (LLY) Earns Outperform Rating from Leerink Swann

Eli Lilly and Co. (NYSE:LLY)‘s stock had its “outperform” rating reaffirmed by stock analysts at Leerink Swann in a note issued to investors on Saturday. They presently have a $92.00 target price on the stock, down from their prior target price of $102.00. Leerink Swann’s price objective indicates a potential upside of 33.10% from the stock’s previous close.

A number of other brokerages have also issued reports on LLY. Citigroup Inc. reissued a “buy” rating on shares of Eli Lilly and in a report on Tuesday, November 8th. Zacks Investment Research raised shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $93.00 price target on the stock in a report on Friday, July 29th. JPMorgan Chase & Co. set a $85.00 price target on shares of Eli Lilly and and gave the stock a “buy” rating in a report on Thursday. BMO Capital Markets reissued an “outperform” rating and issued a $94.00 price target on shares of Eli Lilly and in a report on Tuesday, September 27th. Finally, Goldman Sachs Group Inc. reissued a “buy” rating and issued a $95.00 price target on shares of Eli Lilly and in a report on Wednesday, October 26th. Four equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $108.34.

Eli Lilly and (NYSE:LLY) traded up 1.65% during midday trading on Friday, hitting $69.12. 8,620,682 shares of the stock traded hands. The stock has a market capitalization of $73.11 billion, a P/E ratio of 30.07 and a beta of 0.28. The stock’s 50-day moving average price is $76.69 and its 200-day moving average price is $77.92. Eli Lilly and has a 52 week low of $64.18 and a 52 week high of $88.16.

Eli Lilly and (NYSE:LLY) last released its earnings results on Tuesday, October 25th. The company reported $0.88 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.96 by $0.08. Eli Lilly and had a net margin of 11.73% and a return on equity of 23.71%. The business had revenue of $5.19 billion for the quarter, compared to the consensus estimate of $4.23 billion. During the same period in the prior year, the business posted $0.89 EPS. Eli Lilly and’s revenue for the quarter was up 4.7% on a year-over-year basis. Equities research analysts expect that Eli Lilly and will post $3.55 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 9th. Investors of record on Tuesday, November 15th will be given a dividend of $0.51 per share. The ex-dividend date of this dividend is Thursday, November 10th. This represents a $2.04 dividend on an annualized basis and a yield of 2.95%. Eli Lilly and’s dividend payout ratio (DPR) is currently 88.70%.

In related news, insider Maria A. Crowe sold 2,248 shares of Eli Lilly and stock in a transaction dated Wednesday, October 5th. The shares were sold at an average price of $81.37, for a total transaction of $182,919.76. Following the completion of the transaction, the insider now directly owns 94,319 shares of the company’s stock, valued at approximately $7,674,737.03. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 0.20% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the stock. RWC Asset Management LLP boosted its position in shares of Eli Lilly and by 3.7% in the third quarter. RWC Asset Management LLP now owns 712,392 shares of the company’s stock worth $57,177,000 after buying an additional 25,429 shares during the period. ETRADE Capital Management LLC boosted its position in shares of Eli Lilly and by 37.7% in the third quarter. ETRADE Capital Management LLC now owns 12,904 shares of the company’s stock worth $1,036,000 after buying an additional 3,531 shares during the period. D.A. Davidson & CO. boosted its position in shares of Eli Lilly and by 53.1% in the third quarter. D.A. Davidson & CO. now owns 41,009 shares of the company’s stock worth $3,289,000 after buying an additional 14,215 shares during the period. Sheets Smith Wealth Management boosted its position in shares of Eli Lilly and by 28.8% in the third quarter. Sheets Smith Wealth Management now owns 3,801 shares of the company’s stock worth $305,000 after buying an additional 851 shares during the period. Finally, Piedmont Investment Advisors LLC acquired a new position in shares of Eli Lilly and during the third quarter worth about $17,345,000. 75.11% of the stock is owned by institutional investors.

Eli Lilly and Company Profile

Related posts

Leave a Comment